StreetInsider.com News Articles

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Mon, 15 Jun 2026 11:00:00 -0400

Company announcement No. 25 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Copenhagen, Denmark, June 15, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 24 (June 8 - June 12, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Mon, 15 Jun 2026 11:00:00 -0400

Company announcement No. 25 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Mon, 15 Jun 2026 11:00:00 -0400

Company announcement No. 25 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

Mon, 15 Jun 2026 11:00:00 -0400

Company announcement No. 25 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Wolfe Research Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Peerperform

Thu, 11 Jun 2026 05:33:37 -0400

Wolfe Research analyst Alexandria Hammond downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Outperform to Peerperform.

The analyst comments "We downgrade ZEAL to Peer Perform driven by a more cautious outlook on survodutide's commercial opty, underpinned by a relatively unfavorable tolerability profile. And while we like do like petrelintide, we're still years from launch, putting it at a disadvantage vs. peers. High discontinuation rates create a challenging commercial opportunity. At ADA, Zealand (ZEAL) and partner Boehringer Ingelheim (BI, private), presented pivotal results for survodutide ("survo," GLP-1/glucagon agonist). Here, we knew weight loss was mild at 13% (treatment-regimen estimand) at week 76

Wolfe Research Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Peerperform

Thu, 11 Jun 2026 05:33:37 -0400

Wolfe Research analyst Alexandria Hammond downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Outperform to Peerperform.

Wolfe Research Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Peerperform

Thu, 11 Jun 2026 05:33:37 -0400

Wolfe Research analyst Alexandria Hammond downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Outperform to Peerperform.

Wolfe Research Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Peerperform

Thu, 11 Jun 2026 05:33:37 -0400

Wolfe Research analyst Alexandria Hammond downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Outperform to Peerperform.

Wolfe Research Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Peerperform

Thu, 11 Jun 2026 05:33:37 -0400

Wolfe Research analyst Alexandria Hammond downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Outperform to Peerperform.

Wolfe Research Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Peerperform

Thu, 11 Jun 2026 05:33:37 -0400

Wolfe Research analyst Alexandria Hammond downgraded Zealand Pharma A/S (ZEAL:DC) (NASDAQ: ZEAL) from Outperform to Peerperform.

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Wed, 10 Jun 2026 16:00:00 -0400

Company announcement – No. 24 / 2026

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Copenhagen, Denmark, June 10, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.

Please see the attached file(s).

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL)

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Wed, 10 Jun 2026 16:00:00 -0400

Company announcement – No. 24 / 2026

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Please see the attached file(s).

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL)

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Wed, 10 Jun 2026 16:00:00 -0400

Company announcement – No. 24 / 2026

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Please see the attached file(s).

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL)

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Wed, 10 Jun 2026 16:00:00 -0400

Company announcement – No. 24 / 2026

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Please see the attached file(s).

About Zealand Pharma
Zealand Pharma A/S (Nasdaq: ZEAL)

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Mon, 08 Jun 2026 11:05:00 -0400

Company announcement No. 23 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the “Program”) for week 23 (June 1 - June 4, 2026).

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Mon, 08 Jun 2026 11:05:00 -0400

Company announcement No. 23 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Mon, 08 Jun 2026 11:05:00 -0400

Company announcement No. 23 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

Mon, 08 Jun 2026 11:05:00 -0400

Company announcement No. 23 / 2026

Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)

The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, “MAR”) and Commission Delegated Regulation (EU) 2016/1052 (the “Safe

Zealand Pharma raises 10.7 million Danish kroner through warrant exercises

Mon, 08 Jun 2026 11:00:44 -0400

Zealand Pharma A/S (NASDAQ: ZEAL) increased its share capital by DKK 53,183 through the exercise of employee warrants, the Danish biotechnology company announced June 8.

The capital increase resulted from employees exercising 53,183 warrants under the company's employee warrant programs. Zealand Pharma received total proceeds of DKK 10,658,111.70 from the warrant exercises.

The exercise involved two different warrant tranches with varying prices. Employees exercised 7,351 warrants at DKK 90.70 per share and 45,832 warrants at DKK 218 per share.

Each warrant granted employees the right to subscribe for one newly issued Zealand Pharma share at predetermined exercise prices within specific time periods. The

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Mon, 08 Jun 2026 11:00:00 -0400

Company announcement – No. 22 / 2026

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Copenhagen, Denmark, June 8, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 53,183 divided into 53,183 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Mon, 08 Jun 2026 11:00:00 -0400

Company announcement – No. 22 / 2026

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Mon, 08 Jun 2026 11:00:00 -0400

Company announcement – No. 22 / 2026

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Mon, 08 Jun 2026 11:00:00 -0400

Company announcement – No. 22 / 2026

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in p

Sun, 07 Jun 2026 14:30:00 -0400

Company announcement No. 21 / 2026

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.¹

Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in p

Sun, 07 Jun 2026 14:30:00 -0400

Company announcement No. 21 / 2026

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP-1 dual agonist, from baseline.¹

Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved